Dynavax Technologies announced it is reshaping its strategy and operations to prioritize its emerging clinical and preclinical immuno-oncology portfolio. It said it has implemented significant organizational restructuring and cost reductions to align around its immuno-oncology business, while allowing it to advance HEPLISAV-B through the FDA approval process. Dynavax said it has suspended manufacturing for HEPLISAV-B and reduced its global workforce by 38%. The company will incur restructuring costs, currently estimated to be $3.0 million, primarily in first quarter of 2017. Going forward, it expects HEPLISAV-B costs prior to any FDA decision to be less than $1 million per month, and all other operating costs to be less than $60 million per year to support continued development of its oncology program. This restructuring is currently estimated to result in approximately a 40% reduction in cash burn. The company will continue to evaluate the possibility of a partnership to support HEPLISAV-B as it increasingly concentrates its own strategic focus on oncology.